The rising popularity of weight-loss drugs, particularly GLP-1 medications, has prompted India’s drug regulatory authorities to take action. Recent raids conducted in various parts of the country have highlighted how easily these prescription-only drugs are reaching consumers. Inspections carried out at 49 different locations, including online pharmacies, wholesalers, retail chemists, and wellness clinics, have exposed significant flaws in the distribution and promotion of these medications.

Shifting Usage from Diabetes Treatment to Weight Loss

Originally intended for managing diabetes and certain cardiovascular conditions, GLP-1 drugs have gained traction as weight-loss solutions. This surge is largely attributed to social media discussions and an increasing demand for rapid results. The influx of generic versions into the Indian market has further enhanced their availability. However, this newly found accessibility has raised alarming concerns regarding misuse and improper distribution practices.

Regulatory Intervention and Measures

In response to these concerns, the Drugs Controller General of India, in collaboration with state regulators, is actively working to address the situation. Initiatives include halting sales without prescriptions, scrutinizing dubious dispensing methods, and taking action against misleading advertisements. The authorities are particularly disturbed by the expanding network through which these drugs are being obtained, which now includes not just traditional pharmacies but also online platforms and slimming centers, often operated without sufficient medical supervision.

Warnings on Advertising Practices

This month, regulatory bodies issued directives to manufacturers to prohibit surrogate advertising or indirect marketing techniques that may promote off-label use among consumers. Medical professionals have cautioned that GLP-1 medications should not be treated as mere lifestyle products. When used improperly or without medical oversight, they pose significant health risks and can lead to serious side effects.

Strict Prescription Guidelines in Place

Regulations state that GLP-1 drugs in India are only approved under stringent conditions and must be prescribed by qualified specialists, such as endocrinologists or internal medicine doctors, and in specific cases, cardiologists. The ongoing rise in demand for these medications has led authorities to assert that enforcement actions will become increasingly rigorous. This may involve revoking licenses, imposing fines, and initiating legal proceedings against violators.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share